Detection and Characterization of Extended-spectrum Beta-lactamase-producing Enterobacteriaceae in High-risk Patients in an Irish Tertiary Care Hospital
Overview
Infectious Diseases
Authors
Affiliations
Background: Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) are Gram-negative, multi-drug-resistant organisms that are of major clinical significance among immunocompromised patients in high-risk areas in hospital settings. In Ireland, the number of ESBL-E bloodstream infections is increasing.
Aims: To conduct a prevalence study of ESBL-E among immunocompromised patients in high-risk areas [intensive care unit (ICU), liver transplantation and haematology/oncology wards], characterize any ESBL genes detected by polymerase chain reaction (PCR), and perform epidemiological typing using pulsed-field gel electrophoresis (PFGE).
Methods: In total, 317 non-duplicate rectal swabs from patients in high-risk wards were screened anonymously for ESBL-E carriage. Positive isolates were characterized using PCR to detect blaCTX-M, blaTEM, blaOXA-1 and blaSHV ESBL-E genes. Clonal relationships of these isolates were investigated using PFGE.
Findings: Fifty (15.8%) high-risk patients were found to harbour ESBL-E. Prevalence rates of 21.9% (N = 28), 14.3% (N = 15) and 8.3% (N = 7) of ESBL-E were isolated from patients on the liver transplantation, ICU and haematology/oncology wards, respectively. Seventy percent of ESBL-E isolates carried more than one resistance gene. Of the 25 ESBL-producing Escherichia coli isolates typed by PFGE, two pairs of two isolates demonstrated >80% homology, and four of the five ESBL-producing Enterobacter cloacae isolates typed by PFGE demonstrated >80% homology, suggesting clonal relatedness and potential cross-transmission from individual patients.
Conclusion: A significant proportion of the patients screened were found to be colonized with ESBL-E. Typing revealed three incidents of potential cross-infection. Therefore, timely detection of ESBL-E among patients in high-risk wards is critical for treatment and infection control.
Dolci G, Burastero G, Paglia F, Cervo A, Meschiari M, Guaraldi G Microorganisms. 2023; 11(6).
PMID: 37375108 PMC: 10304660. DOI: 10.3390/microorganisms11061606.
Abrar S, Ain N, Liaqat H, Hussain S, Rasheed F, Riaz S Antimicrob Resist Infect Control. 2019; 8:80.
PMID: 31139363 PMC: 6530043. DOI: 10.1186/s13756-019-0536-0.
Prevel R, Boyer A, Mzali F, Lasheras A, Zahar J, Rogues A Crit Care. 2019; 23(1):170.
PMID: 31088542 PMC: 6518813. DOI: 10.1186/s13054-019-2460-3.
Jorgensen S, Soraas A, Sundsfjord A, Liestol K, Leegaard T, Jenum P PLoS One. 2017; 12(3):e0173510.
PMID: 28267783 PMC: 5340397. DOI: 10.1371/journal.pone.0173510.
Colonisation with extended-spectrum beta-lactamase (ESBL) not detected in a prevalence study.
OConnor C, Kiernan M, Finnegan C, Powell J, Power L, OConnell N Ir J Med Sci. 2016; 186(3):723-727.
PMID: 27761798 DOI: 10.1007/s11845-016-1505-8.